INOVIO (NASDAQ:INO), an American biotechnology company, announced on Tuesday that it has named Steven Egge as its new chief commercial officer.

In the new role, Egge will head the firm's commercial strategy and operations as it prepares to potentially introduce its first DNA medicine product, INO-3107, as a treatment for recurrent respiratory papillomatosis (RRP).

Egge has served as senior vice president and general manager for Women's Health at Sumitomo Pharma. He has served at Merck for 20 years, where he served in various senior commercial leadership roles, including heading Merck's HPV Vaccines Franchise and chief marketing officer for the Vaccine Division. He has also served as global commercial head for Merck's Fertility Franchise and senior vice president at Genfit Corp.

Dr Jacqueline Shea, INOVIO's president and chief executive officer, said: "We are delighted to welcome Steve to INOVIO and look forward to adding his expertise to our leadership team as we continue advancing our preparations to commercially launch INO-3107 in 2025, should it receive approval by the FDA as a treatment for RRP. Steve joins us at an exciting time, as we prepare to become a commercial-stage company, while advancing multiple product candidates targeting unmet medical needs. His expertise launching new products, driving market share in competitive environments, and growing overall therapeutic areas will be advantageous to the development and implementation of our commercial plans, as will his experience across immunology and vaccines, HPV, and rare diseases."